HSCT operational characteristics
| . | Case cohort A . | Control cohort B . | Control cohort C . | P . | |
|---|---|---|---|---|---|
| . | 3/15/20 to 6/15/20 . | 12/15/19 to 3/14/20 . | 3/15/19 to 6/15/19 . | A vs B . | A vs C . |
| Allogeneic HSCT | |||||
| Patient, n | 64 | 68 | 76 | ||
| Accrual rate per month | 21.2 | 23 | 25.1 | ||
| Operational | |||||
| Referral source | |||||
| Internal | 35 (54.7) | 39 (57.4) | 35 (46.1) | ||
| Domestic | 29 (45.3) | 29 (42.6) | 41 (53.9) | ||
| International | 0 | 0 | |||
| Context, n (%) | .0008 | <.0001 | |||
| Inpatient | 46 (71.9) | 64 (94.1) | 75 (98.7) | ||
| Ambulatory | 18 (28.1) | 4 (5.9) | 1 (1.3) | ||
| Hospital length of stay, d | .24 | .001 | |||
| Median (range) | 24 (7, 75) | 23.5 (2,67) | 20 (2, 54) | ||
| Product cryopreserved, n (%) | <.0001 | <.0001 | |||
| No | 32 (50) | 64 (94.1) | 72 (94.7) | ||
| Yes | 32 (50) | 4 (5.9) | 4 (5.3) | ||
| Product procurement | |||||
| Workup to day 0, median (range), d | 43 (18, 121) | 42.5 (17, 157) | 43 (22, 190) | .79 | .33 |
| Product source, n (%) | |||||
| Marrow | 10 (21.7) | 10 (17.9) | 16 (27.6) | .63 | .65 |
| PBSC | 36 (78.3) | 46 (82.1) | 42 (72.4) | ||
| Primary/secondary* | |||||
| Primary | 44 (95.7) | 56 (100) | 57 (98.3) | .21 | .58 |
| Secondary | 2 (4.3) | 1 (1.7) | |||
| Product origin, n (%) | |||||
| Domestic | 29 (63) | 21 (37.5) | 31 (53.4) | .017 | .42 |
| International | 17 (37) | 35 (62.5) | 27 (46.6) | ||
| Autologous HSCT | |||||
| Patients, n | 39 | 43 | 54 | ||
| Accrual rate per month | 12.9 | 14.5 | 17.9 | ||
| Operational | |||||
| Referral source, n (%) | .16 | .04 | |||
| Internal | 23 (59) | 17 (39.5) | 18 (33.3) | ||
| Domestic | 16 (41) | 25 (58.1) | 35 (64.8) | ||
| International | 0 | 1 (2.3) | 1 (1.9) | ||
| Hospital length of stay, d | .03 | .004 | |||
| Median (range) | 20 (15, 29) | 20 (15,30) | 19 (15, 41) | ||
| . | Case cohort A . | Control cohort B . | Control cohort C . | P . | |
|---|---|---|---|---|---|
| . | 3/15/20 to 6/15/20 . | 12/15/19 to 3/14/20 . | 3/15/19 to 6/15/19 . | A vs B . | A vs C . |
| Allogeneic HSCT | |||||
| Patient, n | 64 | 68 | 76 | ||
| Accrual rate per month | 21.2 | 23 | 25.1 | ||
| Operational | |||||
| Referral source | |||||
| Internal | 35 (54.7) | 39 (57.4) | 35 (46.1) | ||
| Domestic | 29 (45.3) | 29 (42.6) | 41 (53.9) | ||
| International | 0 | 0 | |||
| Context, n (%) | .0008 | <.0001 | |||
| Inpatient | 46 (71.9) | 64 (94.1) | 75 (98.7) | ||
| Ambulatory | 18 (28.1) | 4 (5.9) | 1 (1.3) | ||
| Hospital length of stay, d | .24 | .001 | |||
| Median (range) | 24 (7, 75) | 23.5 (2,67) | 20 (2, 54) | ||
| Product cryopreserved, n (%) | <.0001 | <.0001 | |||
| No | 32 (50) | 64 (94.1) | 72 (94.7) | ||
| Yes | 32 (50) | 4 (5.9) | 4 (5.3) | ||
| Product procurement | |||||
| Workup to day 0, median (range), d | 43 (18, 121) | 42.5 (17, 157) | 43 (22, 190) | .79 | .33 |
| Product source, n (%) | |||||
| Marrow | 10 (21.7) | 10 (17.9) | 16 (27.6) | .63 | .65 |
| PBSC | 36 (78.3) | 46 (82.1) | 42 (72.4) | ||
| Primary/secondary* | |||||
| Primary | 44 (95.7) | 56 (100) | 57 (98.3) | .21 | .58 |
| Secondary | 2 (4.3) | 1 (1.7) | |||
| Product origin, n (%) | |||||
| Domestic | 29 (63) | 21 (37.5) | 31 (53.4) | .017 | .42 |
| International | 17 (37) | 35 (62.5) | 27 (46.6) | ||
| Autologous HSCT | |||||
| Patients, n | 39 | 43 | 54 | ||
| Accrual rate per month | 12.9 | 14.5 | 17.9 | ||
| Operational | |||||
| Referral source, n (%) | .16 | .04 | |||
| Internal | 23 (59) | 17 (39.5) | 18 (33.3) | ||
| Domestic | 16 (41) | 25 (58.1) | 35 (64.8) | ||
| International | 0 | 1 (2.3) | 1 (1.9) | ||
| Hospital length of stay, d | .03 | .004 | |||
| Median (range) | 20 (15, 29) | 20 (15,30) | 19 (15, 41) | ||
The NMDP defines primary collection as the first donation event for a particular recipient-donor pairing. Secondary collection refers to subsequent donation of this original pairing (eg, for a stem cell boost).